600161.SHG Beijing Tiantan Biological Products Corp Ltd
- Market cap
- CNY 25.4B
- P/E
- 35.7x
- P/B
- 2.13x
- ROE
- 4.8%
- Dividend yield
- 1.95%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600161.SHG undervalued?
Graham number600161.SHG trades 84.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Tiantan Biological Products Corp Ltd fundamental analysis
No fundamental analysis for Beijing Tiantan Biological Products Corp Ltd yet.
Beijing Tiantan Biological Products Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepati…
Full company profileBeijing Tiantan Biological Products Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Tiantan Biological Products Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.14B | 2.48B | 2.93B | 3.28B | 3.45B | 4.11B | 4.26B | 5.18B | 6.03B | 6.14B | 5.14B |
| Gross Profit | 1.11B | 1.27B | 1.37B | 1.62B | 1.70B | 1.95B | 2.09B | 2.63B | 3.29B | 2.58B | 1.81B |
| Operating Income | 348M | 1.54B | 868M | 1.05B | 1.10B | 1.24B | 1.43B | 1.80B | 2.56B | 1.77B | 1.02B |
| EBITDA | 662M | 941M | 981M | 1.15B | 1.18B | 1.31B | 1.45B | 1.95B | 2.78B | 2.22B | 1.01B |
| Net Income | 257M | 1.17B | 509M | 611M | 639M | 760M | 881M | 1.11B | 1.55B | 1.09B | 571M |
| EPS | 0.17 | 0.78 | 0.34 | 0.41 | 0.42 | 0.47 | 0.53 | 0.56 | 0.78 | 0.55 | 0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 5.78B | 3.67B | 5.07B | 6.31B | 7.54B | 11.6B | 12.9B | 14.2B | 15.9B | 16.6B | 16.8B |
| Total Liabilities | 3.34B | 481M | 720M | 1.14B | 1.51B | 1.31B | 1.58B | 1.43B | 1.34B | 1.22B | 1.26B |
| Shareholders' Equity | 2.19B | 3.04B | 3.37B | 3.94B | 4.52B | 8.05B | 8.80B | 9.82B | 11.1B | 11.7B | 11.9B |
| Cash & Short-term Investments | 660M | 1.76B | 1.25B | 1.41B | 1.75B | 4.33B | 3.71B | 4.55B | 2.69B | 1.99B | 1.90B |
| Total Debt | 2.34B | 200M | 231M | 401M | 801M | 509M | 403M | 24.4M | 44.9M | 187M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 428M | 218M | 678M | 642M | 702M | 980M | 1.13B | 2.39B | 820M | 376M | - |
| Capital Expenditure | 209M | 145M | 294M | 526M | 609M | 1.13B | 1.35B | 1.08B | 1.07B | 606M | 619M |
| Free Cash Flow | 219M | 73.5M | 384M | 116M | 93.2M | -151M | -228M | 1.32B | -248M | -230M | -72.3M |
| Ratios | |||||||||||
| ROE | 11.7% | 38.6% | 15.1% | 15.5% | 14.1% | 9.4% | 10.0% | 11.3% | 13.9% | 9.3% | 4.8% |
| ROA | 4.4% | 32.0% | 10.1% | 9.7% | 8.5% | 6.6% | 6.8% | 7.8% | 9.8% | 6.6% | 3.4% |
| Net Profit Margin | 12.0% | 47.2% | 17.4% | 18.6% | 18.5% | 18.5% | 20.7% | 21.4% | 25.7% | 17.8% | 11.1% |
| Debt to Equity | 1.07x | 0.07x | 0.07x | 0.10x | 0.18x | 0.06x | 0.05x | 0.00x | 0.00x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Tiantan Biological Products Corp Ltd dividends
- Dividend yield
- 1.95%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 45.3%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 494M | 0.25 | 45.3% |
| 2024 | CNY 247M | 0.12 | 16.0% |
| 2023 | CNY 82.4M | 0.04 | 7.4% |
| 2022 | CNY 137M | 0.08 | 15.6% |
| 2021 | CNY 137M | 0.09 | 18.1% |
| 2020 | CNY 62.7M | 0.04 | 9.8% |
| 2019 | CNY 43.6M | 0.03 | 7.1% |
| 2018 | CNY 140M | 0.09 | 27.5% |
| 2017 | CNY 186M | 0.12 | 15.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 20, 2024.
Who owns Beijing Tiantan Biological Products Corp Ltd
- Insiders 57.01%
- Institutions 3.22%
- Public & others 39.77%
- Shares outstanding 1.98B
- Free float 862M
Beijing Tiantan Biological Products Corp Ltd company profile
- Company name
- Beijing Tiantan Biological Products Corp Ltd
- Ticker
- 600161.SHG
- ISIN
- CNE000000WF9
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 18, 1998
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5,205
- Fiscal year end
- December
- Address
- No.B2 Shuangqiao Road, Beijing, China, 100024
- Phone
- 86 10 6543 4018
- Website
- tiantanbio.com
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.
Beijing Tiantan Biological Products Corp Ltd management
4- Mr. Hui Chuan YangGM & Director · born 1969
- Mr. Hongqing WangChief Financial Officer · born 1982
- Mr. Yanlin HeDeputy General Manager · born 1968
- Mr. Ding YuDeputy General Manager · born 1976